A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 884 participants.
Also called NCT01191268
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 884 participants
- Sponsor
- Registry
-
NCT01191268
-
- Other papers using this trial's data
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Greece, Hungary, Mexico, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01191268. Randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2014-10-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- LY2189265
- Intervention (Drug)
- Insulin Lispro
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01191268- Content hash
eb0f390fa16fe3b5721f22d11979b97b36e4749c6174fa268224ee5fe593081f